Stoke Therapeutics STOK 深 滬
已收盤 12-05 16:00:00 美东时间
30.87
-0.180
-0.58%
華盛通- 最 高32.09
- 今 開31.13
- 成交量 60.28万股
- 最 低 30.26
- 昨 收 31.05
- 總市值 16.92亿
- 52周最高 38.693
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 5.35
- 委 比 87.79%
- 總股本 5479.74万
- 歷史最高 71.58
- 量 比 0.96
- 振 幅 5.89%
- 歷史最低 3.35
- 每 手 1
- 風險率 7.92%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Stoke Therapeutics Highlights Zorevunersen’s Potential at Epilepsy Meeting
The latest announcement is out from Stoke Therapeutics ( ($STOK) ). At the 2025...
12-05 22:28
Biogen And Stoke Therapeutics To Present Data From Studies Of Zorevunersen At 2025 AES Annual Meeting
Biogen Inc. (NASDAQ:BIIB) and Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced data
12-01 20:40
Biogen And Stoke Therapeutics Highlight Urgent Need For New Medicines Targeting Underlying Genetic Cause Of Dravet Syndrome To Improve Long Term Outcomes
– Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative to children with
11-17 20:38
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
6 Analysts Have This To Say About Stoke Therapeutics
Analysts' ratings for Stoke Therapeutics (NASDAQ:STOK) over the last quarter va...
11-05 19:45
Earnings Scheduled For November 4, 2025
Companies Reporting Before The Bell • Sequans Communications (NYSE:SQNS) is lik...
11-04 19:12
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
11-04 10:31
Examining the Future: Stoke Therapeutics's Earnings Outlook
Stoke Therapeutics (NASDAQ:STOK) is preparing to release its quarterly earnings...
11-04 04:02
JP Morgan Maintains Neutral on Stoke Therapeutics, Raises Price Target to $25
JP Morgan analyst Jessica Fye maintains Stoke Therapeutics (NASDAQ:STOK) with a Neutral and raises the price target from $15 to $25.
11-03 23:53
Stoke Therapeutics Unveils Two-Year Data Offering Hope For Patients With Rare Genetic Vision Disorder
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicines, today announced the presentation of two-year data from the
10-20 19:36
